JAK inhibitor Ruxolitinib phosphate, Purity ≥98%

Cat. No.: X23-10-ZQ413

JAK inhibitor Ruxolitinib phosphate, Purity ≥98%

Synonym: Ruxolitinib phosphate; 1092939-17-7; Jakafi; Jakavi; (R)-3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate; OPZELURA; Ruxolitinib (phosphate); JAK inhibitor

  • MDL: MFCD18452860
  • CAS Number: 1092939-17-7
  • Compound CID: 25127112
Product Size
5 mg; 10 mg; 25 mg; 50 mg; 100 mg
Price
Datasheet
MSDS
Properties
Description
Ruxolitinib phosphate, soluble in DMSO, water and ethanol, is an available JAK small molecule inhibitor with potential antineoplastic activity. It targets JAK1, JAK2, JAK3, and Tyk2.
Molecular Weight
404.37
Molecular Formula
C17H21N6O4P
Targets
JAK1: 3.3 nM; JAK2: 2.8 nM; JAK3: 428 nM; Tyk2: 19 nM
Form
Lyophilized powder
Purity
≥98%
Solubility
DMSO: 73 mg/mL (180.53 mM); Water: 26 mg/mL (64.29 mM); Ethanol: 7 mg/mL (17.31 mM)
Identity
Confirmed by NMR/HPLC/MS.
Stability
The product is stable for three years when stored at the recommended temperature in lyophilized powder.
Applications
Ruxolitinib phosphate is used to study JAK1 and JAK2 selective inhibition.
Storage
Store at -20ºC.
Related Products

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.